CagriSema for Weight Loss
Research, mechanism, dosing, and effectiveness of CagriSema for weight loss.
Quick Answer
CagriSema combines cagrilintide and semaglutide for potentially superior weight loss.
Evidence Level
Human Trials
Typical Dose
Combined weekly injection (Phase 3 trials)
Results Timeline
Weight loss in trial participants
FDA Status
Research Only
How CagriSema Works for Weight Loss
Dual amylin and GLP-1 action for enhanced metabolic effects.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment.
Dosing for Weight Loss
Recommended Dose
Combined weekly injection (Phase 3 trials)
Frequency
See research protocols
Administration
Subcutaneous injection weekly
Duration
Long-term use expected
Note: Limited anecdotal data. Refer to research dosing section.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •GI events (72-80% vs 34-40% placebo)
- •Higher GI effects than semaglutide alone
Frequently Asked Questions
Does CagriSema help with weight loss?
CagriSema combines cagrilintide and semaglutide for potentially superior weight loss.
How does CagriSema work for weight loss?
Dual amylin and GLP-1 action for enhanced metabolic effects....
What dose of CagriSema should I use for weight loss?
Combined weekly injection (Phase 3 trials)
How long until I see results?
Weight loss in trial participants
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Orforglipron
FDAAn oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.